Advertisement


Chirag Shah, MD, on Assessing DCIS Recurrence Risk

2020 San Antonio Breast Cancer Symposium

Advertisement

Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study found that despite using traditional favorable-risk criteria, radiation recommendations were changed in more than 40% of patients (Abstract PS6-17).



Related Videos

Breast Cancer

Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival

In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is ass...

Breast Cancer

Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat

Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in arom...

Breast Cancer

Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with cl...

Breast Cancer

Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment

Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to...

Breast Cancer
Immunotherapy

Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy

Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs ch...

Advertisement

Advertisement



Advertisement